A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

ConclusionsThe pirfenidone 801-mg tablet met bioequivalence criteria when compared with three 267-mg capsules in the fasted state. The tabletCmax was slightly higher relative to capsules in the fed state, but this is not expected to have a clinically meaningful impact on the benefit –risk profile of pirfenidone.FundingThis work was supported by F. Hoffmann-La Roche Ltd.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research